AZTherapies, which is developing an inhaled cromolyn/oral ibuprofen combination therapy for the treatment of Alzheimer’s disease, has appointed former Pfizer executive Karen Reeves as President and Chief Medical Officer. The company’s ALZT-OP1 combination is currently in Phase 3 development.
Reeves was most recently VP, Head Global Clinical Submissions Quality and Innovation, Worldwide Research and Development, at Pfizer. She was also previously at VP, Head of Global Medical Science at Astellas.
AZTherapies Founder, Chairman, and CEO David Elmaleh commented, “We are excited to welcome Dr. Karen Reeves to AZTherapies as President and Chief Medical Officer. Dr. Reeves brings tremendous experience in over twenty years in big pharma and provides additional clinical development, business development, and management expertise to the talented AZTherapies management team. We are delighted to have Dr. Reeves’ leadership as we move forward with our advanced product candidates.”
Reeves said, “I’m thrilled and honored to join AZTherapies’ senior management at this most important time. Alzheimer’s disease and stroke are devastating and heartbreaking neurological diseases for patients and families that demand better and newer treatments. The COGNITE trial in early AD is currently enrolling patients globally and has randomized over 280 patients. AZTherapies’ combination therapy has the potential to address multiple mechanisms associated with amyloid plaques, neurodegeneration, and neuroinflammation that could potentially dampen neural death and neuroinflammation and lead to better outcomes for patients with Alzheimer’s and other neurological diseases.”
Read the AZTherapies press release.
